The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A

N. Gleicher*, D. F. Albertini, D. H. Barad, H. Homer, D. Modi, M. Murtinger, P. Patrizio, R. Orvieto, S. Takahashi, A. Weghofer, S. Ziebe, N. Noyes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Background: A recently published Position Statement (PS) by the Preimplantation Genetics Diagnosis International Society (PGDIS) regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF) contained inaccuracies and misrepresentations. Because opinions issued by the PGDIS have since 2016 determined worldwide IVF practice, corrections appear of importance. Methods: The International Do No Harm Group in IVF (IDNHG-IVF) is a spontaneously coalesced body of international investigators, concerned with increasing utilization of add-ons to IVF. It is responsible for the presented consensus statement, which as a final document was reached after review of the pertinent literature and again revised after the recent publication of the STAR trial and related commentaries. Results: In contrast to the PGDIA-PS, we recommend restrictions to the increasing, and by IVF centers now often even mandated, utilization of PGT-A in IVF cycles. While PGT-A has been proposed as a tool for achieving enhanced singleton livebirth outcomes through embryo selection, continued false-positive rates and increasing evidence for embryonic self-correction downstream from the testing stage, has led IDNHG-IVF to conclude that currently available data are insufficient to impose overreaching recommendations for PGT-A utilization. Discussion: Here presented consensus offers an alternative to the 2019 PGDIS position statement regarding utilization of preimplantation genetic testing for aneuploidy (PGT-A) in association with in vitro fertilization (IVF). Mindful of what appears to offer best outcomes for patients, and in full consideration of patient autonomy, here presented opinion is based on best available evidence, with the goal of improving safety and efficacy of IVF and minimizing wastage of embryos with potential for healthy births. Conclusions: As the PGDIS never suggested restrictions on clinical utilization of PGT-A in IVF, here presented rebuttal represents an act of self-regulation by parts of the IVF community in attempts to control increasing utilization of different unproven recent add-ons to IVF.

Original languageEnglish
Article number57
JournalReproductive Biology and Endocrinology
Volume18
Issue number1
DOIs
StatePublished - 29 May 2020

Keywords

  • Embryo selection
  • In vitro fertilization (IVF)
  • Live birth rates
  • Miscarriage rates
  • Pregnancy rates
  • Preimplantation genetic screening (PGS)
  • Preimplantation genetic testing for aneuploidy (PGT-A)

Fingerprint

Dive into the research topics of 'The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A'. Together they form a unique fingerprint.

Cite this